Postprandial metabolism of apolipoproteins B48, B100, C-III, and E in humans with APOC3 loss-of-function mutations

BACKGROUND: Apolipoprotein C-III (apoC-III) is a regulator of triglyceride (TG) metabolism, and due to its association with risk of cardiovascular disease, is an emergent target for pharmacological intervention. The impact of substantially lowering apoC-III on lipoprotein metabolism is not clear. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Taskinen, Marja-Riitta, Björnson, Elias, Matikainen, Niina, Söderlund, Sanni, Rämö, Joel, Ainola, Mari-Mia, Hakkarainen, Antti, Sihlbom, Carina, Thorsell, Annika, Andersson, Linda, Bergh, Per-Olof, Henricsson, Marcus, Romeo, Stefano, Adiels, Martin, Ripatti, Samuli, Laakso, Markku, Packard, Chris J., Borén, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2022
Materias:
Clinical Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675484/
https://www.ncbi.nlm.nih.gov/pubmed/36040803
http://dx.doi.org/10.1172/jci.insight.160607

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9675484/
https://www.ncbi.nlm.nih.gov/pubmed/36040803
http://dx.doi.org/10.1172/jci.insight.160607

Ejemplares similares